|
|
|
|
|
★ Highrisingstocks Alert: PositiveID Corporation (OTCQB) PSID ★
52Week-low FastSTO FAST Bounce Trade (15Minute CandleVOL) BOTTOM
|
|
|
|
|
|
|
|
|
Welcome To PositiveID Corporation™ (OTCQB) PSID
|
|
|
|
Advanced biological detection and diagnostic solutions for homeland security and global healthcare needs. PositiveID Corporation™ (OTCQB: PSID) is an emerging growth company and developer of biological detection and diagnostic systems for America's homeland defense and the global healthcare market.
PositiveID specializes in the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats and outbreaks, whether airborne, in a healthcare setting, or at the point of need.
PositiveID develops biological detection and diagnostics systems, including its M-BAND and Firefly Dx systems, which use real-time polymerase chain reaction (PCR) chemistry. PCR amplifies a sample’s DNA and copies it billions of times. PCR is used every day to diagnose diseases, identify bacteria and viruses, and for many other applications. With real-time PCR, the amplification of the DNA can be measured as it occurs, thereby speeding up the ability to deliver results. Real-time PCR is one of the most sensitive and specific bio-detection capabilities available today.
Why (OTCQB) PSID? Man who died from Ebola endured treatment delays!
OMAHA, Neb. (AP) -- A surgeon who contracted Ebola in his native Sierra Leone did not receive aggressive treatment until nearly two weeks after he first started showing symptoms - a delay that doctors said probably made it impossible for anyone to save his life.
Dr. Martin Salia was in the 13th day of his illness when he reached Omaha on Saturday. It took three days for him to be formally diagnosed after an initial test for Ebola came back negative and then another five days to be flown to the United States.
By the time the 44-year-old Maryland man got to the University of Nebraska Medical Center in Omaha, the deadly virus had done too much damage, shutting down Salia's kidneys and making breathing difficult, doctors said. He died Monday, Continue Reading...
|
|
|
|
|
(OTCQB) PSID | Recent Developments
|
|
|
|
|
PositiveID Corporation™ Announces First Quarter Highlights
Company Makes Significant Progress in First Quarter With Firefly Dx Development and Testing; Achieves PCR Results in Less Than 20 Minutes on PCR Chip
DELRAY BEACH, Fla., April 15, 2015 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (PSID), a developer of biological detection and diagnostics solutions, today announced its first quarter highlights, primarily related to the Company's continued progress with the development and testing of its Firefly Dx, a handheld, point-of-need, real-time PCR (polymerase chain reaction) pathogen detection system.
First Quarter 2015 Highlights:
- Completed the design of the second-phase (bench-top) prototype of Firefly Dx, the first major milestone in the development of the second-phase prototype
- Commenced building the second-phase prototype of Firefly Dx
- Prepared additional M-BAND systems for field deployment and testing
- Issued revenue guidance of 3-6 million for 2015
- Completed the build of its Firefly Dx PCR chip, and started testing assays to prove the design of achieving PCR results in less than 20 minutes
- Filed a new U.S. patent for Firefly Dx: "A Cyclical and Continuous Flow PCR Device," which covers a cyclical mechanism of thermal cycling required to complete real-time PCR and deliver results in less than 20 minutes
- Filed additional U.S. patent for FireflyDx: "A Cyclical PCR Device w/ Reusable Heat Zones"
- Completed additional testing of its phase II Firefly Dx, and detected multiple organisms with a multiplex assay designed to simultaneously test up to 4 pathogens on PCR chip
"As we continue to advance the development and testing of Firefly Dx, which is being built to capitalize on a multi-billion dollar market opportunity and unmet requirement for point-of-need, real-time PCR testing, we are excited with our progress to date and the opportunity to deliver a system that could revolutionize the way biological samples are tested, while delivering significant value to our stockholders," stated William J. Caragol, Chairman and CEO of PositiveID.
Firefly Dx is designed to provide real-time, accurate diagnostic results in a handheld device, thereby leading to treatment scenarios at the point of need that are not possible with existing systems, which require lab-based equipment and can take hours or even days to provide results. Firefly's applications include point-of-need, lab-quality, detection of pathogenic organisms; agricultural screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction.
Firefly Dx is targeting the global PCR market, which is projected to reach approximately 27.4 billion this year, according to a Research and Markets' report Polymerase Chain Reaction (PCR) - Products/Tools - A Global Market Watch, 2009-2015.
|
|
|
|
(OTCQB) PSID | Recent Headlines
|
|
|
|
- PositiveID Corporation Discusses Firefly Dx Development Progress in New Interview
- PositiveID Announces First Quarter Highlights GlobeNewswire(Wed, Apr 15)
- POSITIVEID CORP FinancialsEDGAR Online Financials(Fri, Apr 3)
- PositiveID Successfully Detects Multiple Organisms From a Single Assay on Its Firefly Dx PCR ChipGlobeNewswire (Thu, Apr 2)
- POSITIVEID CORP Files SEC form 10-K, Annual ReportEDGAR Online(Mon, Mar 30)
- Ticker Research Issues Company Update On PositiveID Corporation(Mar 24)
- Biotechnology And The Road To Innovation: What Companies Are Pushing New Innovation In Today's Market?Accesswire(Thu, Mar 19)
- PositiveID Corporation Files Additional U.S. Patent for Its Firefly Dx Real-Time PCR SystemGlobeNewswire(Wed, Mar 18)
- PositiveID Announces First Firefly Dx Testing and Delivery of Positive PCR Results Within 20 MinutesGlobeNewswire(Thu, Mar 12)
- PositiveID Poised To Carve Out Its Share of the 27.4 Billion Global Polymerase Chain Reaction (PCR) Market in 2015: Analyst Report (Thu, Mar 12)
- PositiveID Corporation Files U.S. Patent for Its Firefly Dx Real-Time PCR SystemGlobeNewswire(Wed, Mar 4)
- PositiveID Corporation Launches New Website at www.psidcorp.com(Wed, Feb 25)
- Tech Takes Center Stage As New Innovation Blazes New TrailsAccesswire(Thu, Feb 19)
- SeeThruEquity Issues Update Note on PositiveID CorporationAccesswire(Tue, Feb 17)
- PositiveID Corporation Achieves Firefly Dx Development Milestone With Completion of Breadboard PCRGlobeNewswire (Thu, Feb 12)
http://finance.yahoo.com/q?s=psid&ql=1
|
|
|
|
|
★ Highrisingstocks Alert: PositiveID Corporation (OTCQB) PSID ★
52Week-low FastSTO FAST Bounce Trade (15Minute CandleVOL) BOTTOM
|
|
|
|
|
|
|
|
| Disclaimer - Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing. You should not invest or trade in any penny stock unless are you are fully prepared, willing, able and expect to lose a hundred pct of your funds,including any profiled company or other company in any other manner mentioned or alluded to by carriage consulting as defined in any medium whatsoever. Carriage Consulting Group Compensation: three thousand dollars for a one day awareness campaign on psid from a 3rdparty The service is provided as a guide to some available investments only, which must be tempered by the investment experience and independent decision making process of the subscriber. The accuracy of issuer documents and information that is submitted to and, its affiliated members and its management for inclusion on this site is principally the responsibility of the particular issuer and its management, its affiliated members and its management is neither responsible for, nor undertakes any steps to check, the accuracy of any information provided by featured companies to potential investors. You should confirm to your own satisfaction the veracity of any info prior to entering into any investment. |
|
|
